Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban

Table 4 Odds ratios for the morbidity of MACCE

Variable	OR	95 % CI	P
Male	0.784	0.454–1.356	0.384
Age	1.017	0.994–1.041	0.155
ACS	1.024	0.806–1.300	0.848
Diabetes	2.028	1.298–3.169	0.002
Creatinine	0.991	0.977–1.005	0.206
Prior PCI	1.424	0.821–2.471	0.208
Prior myocardial infarction	1.126	00619–2.047	0.697
NYHA functional classification	1.035	0.663–1.614	0.881

ACS Acute coronary syndrome. P < 0.05 was considered to indicate statistical significance

ISSN: 2054-9369